Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovativ...
resTORbio, Inc. is a clinical-stage biopharmace...
Optinose is a specialty pharmaceutical company focused on creating and bringing to...
Optinose is a specialty pharmaceutical company ...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
Avid Bioservices is a dedicated contract development and manufacturing organizatio...
Avid Bioservices is a dedicated contract develo...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.